Akari Therapeutics to Present at the 2026 Biotech Showcase
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Abizer Gaslightwala, President and CEO, will overview Akari’s ADC platform, strategic priorities and key milestones for 2026. Management will also be available for in-person one-on-one meetings with registered, qualified investors during the conference running January 12–14, 2026.
Positive
- None.
Negative
- None.
Details
News Market Reaction – AKTX
In the Jan 8 session, AKTX declined 1.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Presentation date
- January 13, 2026
- In-person Biotech Showcase presentation
- Presentation time
- 9:30 AM PT
- Biotech Showcase session slot
- Conference dates
- January 12–14, 2026
- 2026 Biotech Showcase in San Francisco
Historical Context
-
Letter outlining 2025 ADC progress and 2026–2027 clinical plans.
-
Start of GMP manufacturing for AKTX-101 with WuXi XDC.
-
Virtual investor segment explaining PH1 payload and AKTX-101 plans.
-
Approx. $5M direct offering and private placement with warrants.
-
AKTX-101 preclinical efficacy data in K-Ras mutant PDAC models.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody drug conjugates medical
adc platform medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In-person presentation on Tuesday, January 13th at 9:30 AM PT
As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026
TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA.
Presentation details are as follows:
Date/Time: Tuesday, January 13, 2026 at 9:30 AM PST
Location: Yosemite A (Ballroom Level)
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGF3, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.